Vaxcyte 3Q 2026: Net loss $297M, EPS $(1.99) — 10-Q Summary
Vaxcyte reported a net loss of $297M in 3Q 2026, up 39.6% YoY, with EPS at $(1.99). The company advanced vaccine trials, with VAX-31 meeting primary endpoints in Phase 3. R&D costs rose 54% YoY due to manufacturing and trial activities.
How this was made
The 30-second read
Why it matters
The widened loss and increased R&D spend suggest near‑term cash pressure, but progress in Phase 3 trials and new manufacturing capacity could be catalysts later.
Market read
Primary relevance is to Vaxcyte shareholders; limited spillover to the broader biotech sector.
What to watch
Lonza's new manufacturing suite could improve margins later; upcoming trial data in 2027 may offset current loss concerns.
Background
The article is an AI‑generated summary of Vaxcyte's 10‑Q filing, highlighting financial results and trial updates.
Ticker impact
Vaxcyte disclosed its Q3 2026 net loss of $297M and EPS of $(1.99), a widening loss year-over-year.
likely downward pressure as the market prices in higher losses and increased R&D spend
Quarterly loss widening 40% YoY signals higher cash consumption; biotech stocks typically react negatively to loss expansions without offsetting milestones.
Market effects
May weigh on other vaccine and biotech peers as investors gauge trial costs and cash runway.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If Phase 3 data are compelling, the loss could be seen as a short-term cost for long-term upside.
Key entities
- companyVaxcyte, Inc.
Biotech firm developing pneumococcal vaccines.
- partnerLonza
Contract manufacturer that started a dedicated suite for PCV production.